Form 4: J&J Executive Wengel Exercises Options, Sells Shares

Johnson & Johnson's EVP, Chief TO and Risk Officer, Kathryn E. Wengel, exercised stock options and sold shares to cover costs and taxes.

Summary

• Kathryn E. Wengel, EVP, Chief TO and Risk Officer at Johnson & Johnson, exercised 38,945 employee stock options on February 6, 2026, at an exercise price of $101.87 per share.
• Immediately following the exercise, 27,270 shares were disposed of at $239.99 per share to cover the exercise price and associated taxes.
• After these transactions, Wengel directly holds 105,955.8735 shares of Johnson & Johnson Common Stock.
• Additionally, Wengel indirectly holds 281 shares through the Johnson & Johnson Savings Plan's ESOP and 86 shares through the 401k, including dividend reinvestment, as of January 31, 2026.
• The options were auto-exercised just prior to their expiration date of February 8, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting an executive monetizing vested compensation, which is a normal part of long-term incentive plans. The retention of a significant number of shares post-transaction is a positive signal.

Positives

• Executive exercising options indicates a realization of value from long-term incentives.
• The exercise price ($101.87) is significantly lower than the disposition price ($239.99), indicating a substantial gain for the executive.

Negatives

• A portion of shares were sold, which reduces the executive's direct ownership, though this is a common practice for tax and cost coverage.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports a completed insider transaction.

Industry Context

StockSavvy.ai notes that routine insider transactions like option exercises and sell-to-cover are common and generally do not reflect a change in company fundamentals or strategic direction. They are typically part of an executive's long-term compensation plan and personal financial management.

Comparison to Industry Standards

• This transaction is standard practice for executive compensation in large, established pharmaceutical and consumer health companies.
• Executives often exercise options as they approach expiration and sell a portion of the acquired shares to cover the exercise cost and tax liabilities.
• This aligns with typical equity incentive plan structures seen at peers like Pfizer, Merck, and Abbott Laboratories, where executives monetize vested equity while often retaining a significant portion of shares.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact, as it's a routine insider transaction. May be viewed as a positive that an executive is realizing value from their long-term incentives.
• Employees: No direct impact from this specific transaction.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction where an executive exercised stock options and sold a portion of the shares to cover taxes and exercise costs. Such transactions are common and generally do not indicate a change in the company's fundamental outlook or the executive's long-term confidence. The executive retains a substantial number of shares, suggesting continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information warranting a change in investment thesis.

Keywords

Johnson & Johnson, JNJ, Kathryn Wengel, Form 4, Insider Transaction, Stock Options, Executive Compensation, Share Sale, Beneficial Ownership